Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
| العنوان: | Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials |
|---|---|
| المؤلفون: | Neeta Somaiah, Kenneth R. Hess, Robert S. Benjamin, Anthony P. Conley, David S. Hong, Shreyaskumar Patel, Vivek Subbiah, Aung Naing, Funda Meric-Bernstam, Roman Groisberg, Amini Behrang, Siqing Fu, Sarina Anne Piha-Paul, Filip Janku |
| المصدر: | Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-8 (2017) Journal for Immunotherapy of Cancer |
| بيانات النشر: | BMJ, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_treatment, Anti-PD-L1, Medical Records, chemistry.chemical_compound, Antineoplastic Agents, Immunological, 0302 clinical medicine, Checkpoint inhibitor, Alveolar soft part sarcoma, Immunology and Allergy, Aged, 80 and over, Sarcoma, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Rash, Anti-PD-1, 3. Good health, Treatment Outcome, 030220 oncology & carcinogenesis, Molecular Medicine, Female, Immunotherapy, medicine.symptom, Research Article, Adult, medicine.medical_specialty, Immunology, Phase 1, Cancer Vaccines, lcsh:RC254-282, Disease-Free Survival, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, Progression-free survival, Adverse effect, Aged, Pharmacology, Performance status, business.industry, medicine.disease, 030104 developmental biology, chemistry, business, Mifamurtide |
| الوصف: | Background Immunotherapies, specifically those based on immune checkpoint inhibitors, have shown promising activity in multiple tumor types. Other than mifamurtide (MEPACT®) for osteosarcoma approved by European Medicines Agency, there are no approved immunotherapies for sarcomas. Methods We analyzed medical records of patients with advanced sarcoma who were referred to Phase 1 clinic at MD Anderson and received an immunotherapy (checkpoint inhibitors, vaccines, or cytokine based therapies). Clinical parameters including demographics, clinical history, toxicity, and response were abstracted. Results Among 50 patients enrolled in immunotherapy trials (Bone 10; Soft-tissue 40) we found 14 different subtypes of sarcomas. Royal Marsden Hospital (RMH) prognostic score was |
| تدمد: | 2051-1426 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b41c4fa481b213118cb514b6a199c9b2Test https://doi.org/10.1186/s40425-017-0301-yTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b41c4fa481b213118cb514b6a199c9b2 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20511426 |
|---|